Abstract
Introduction: The treatment landscape of metastatic renal cell carcinoma has advanced significantly with the approval of combination regimens containing an immune checkpoint inhibitor (ICI) for patients with treatment-naïve disease. Little information is available regarding the activity of single-agent ICIs for patients with previously untreated mRCC not enrolled in clinical trials. Methods: This retrospective, multicenter cohort included consecutive treatment-naïve mRCC patients from six institutions in the United States who received ≥1 dose of an ICI outside a clinical trial, between June 2017 and October 2019. Descriptive statistics were used to analyze outcomes including objective best response rate (ORR), progression-free survival (PFS), and tolerability. Results: The final analysis included 27 patients, 70% men, median age 64 years (range 42-92), 67% Caucasian, and 33% with ECOG 2 or 3 at baseline. Most patients had intermediate risk (85%, IMDC) with clear cell (56%), papillary (26%), unclassified (11%), chromophobe (4%), and translocation (4%) RCC. All patients had evidence of metastatic disease involving the lungs (59%), lymph node (41%), CNS (19%), liver (11%), adrenal gland (11%), and bone (11%). The median time on IC...Continue Reading
References
Aug 2, 2008·Cancer·Brian ShuchArie S Belldegrun
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Feb 1, 2017·Clinical Genitourinary Cancer·Sumanta K PalNicholas J Vogelzang
Sep 30, 2017·CA: a Cancer Journal for Clinicians·Pedro C Barata, Brian I Rini
Jan 31, 2018·Journal for Immunotherapy of Cancer·Vadim S KoshkinBrian I Rini
Mar 22, 2018·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 214 Investigators
May 26, 2018·British Journal of Cancer·Pedro Coelho BarataBrian I Rini
Feb 20, 2019·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
May 21, 2019·Journal of Immunotherapy·Nalan A Babacan, Tawee Tanvetyanon
Aug 21, 2019·The Lancet Oncology·Moshe C OrnsteinBrian I Rini
Nov 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley A McGregorToni K Choueiri
Dec 2, 2019·European Urology Oncology·Jeffrey GrahamDaniel Y C Heng
Jan 9, 2020·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B I RiniR J Motzer